How to estimate left ventricular hypertrophy in hypertensive patients

Area of Science:

• Cardiology
• Pathophysiology
• Cardiovascular Medicine

Background:

• Left ventricular hypertrophy (LVH) is a cardiac structural remodeling in response to pressure or volume overload.
• Hypertension is not the sole independent factor; comorbidities like obesity, insulin resistance, and genetics play significant roles.
• LVH progresses through adaptive, compensatory, and pathological phases, with contractile dysfunction becoming irreversible in the final stage.

Purpose of the Study:

• To elucidate the multifactorial nature of Left Ventricular Hypertrophy development.
• To highlight the association between LVH and increased cardiovascular event risk.

Main Methods:

• Review of previous studies on LVH pathophysiology and risk factors.
• Analysis of data from the Framingham study regarding LVH prevalence in hypertension.
• Examination of the structural changes in the heart during LVH.

Main Results:

• LVH development is influenced by comorbidities such as triglycerides, age, gender, genetics, insulin resistance, obesity, physical inactivity, salt intake, and chronic stress.
• LVH prevalence increases with hypertension severity, affecting 15-20% of mild and 50% of severe cases.
• Pathophysiology involves cardiomyocyte hypertrophy, fibrosis, and vascular changes, leading to a 2-4 times higher risk of adverse cardiovascular events.

Conclusions:

• LVH is a complex condition driven by multiple factors beyond hypertension.
• Early identification and management of contributing comorbidities are crucial for mitigating LVH progression and cardiovascular risk.